Skye Bioscience, Inc. (SKYE) Balance Sheet

The consistent downward trajectory in total assets suggests that the company is rapidly exhausting its financial resources without achieving a self-sustaining commercial milestone. This trend indicates that the business quality remains highly speculative, as the balance sheet is being utilized primarily as a bridge to potential future clinical data rather than as a foundation for operational growth.

The current ratio of 1.78, while technically above parity, masks the reality that the company lacks recurring revenue to replenish its cash reserves. Investors should monitor the burn rate closely, as the current liquidity profile suggests that the company may be forced to seek dilutive financing in the near term to avoid a total depletion of operating capital.

The erosion of equity highlights the high cost of the company's R&D-heavy business model, where shareholder value is consistently sacrificed to fund the development of the Nimacimab pipeline. This persistent negative trend in retained earnings suggests that the company remains entirely dependent on external equity markets to maintain its solvency, which may lead to further dilution for existing shareholders.